X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DIVIS LABORATORIES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DIVIS LABORATORIES NOVARTIS/
DIVIS LABORATORIES
 
P/E (TTM) x 342.6 18.0 1,900.5% View Chart
P/BV x 16.9 3.9 432.3% View Chart
Dividend Yield % 1.7 1.6 107.8%  

Financials

 NOVARTIS   DIVIS LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-16
DIVIS LABORATORIES
Mar-16
NOVARTIS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9822,484 39.5%   
Low Rs556918 60.6%   
Sales per share (Unadj.) Rs252.9142.3 177.8%  
Earnings per share (Unadj.) Rs62.141.9 148.4%  
Cash flow per share (Unadj.) Rs63.346.3 136.6%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.30.6 221.1%  
Book value per share (Unadj.) Rs363.6161.5 225.1%  
Shares outstanding (eoy) m31.96265.47 12.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.012.0 25.4%   
Avg P/E ratio x12.440.6 30.5%  
P/CF ratio (eoy) x12.236.7 33.1%  
Price / Book Value ratio x2.110.5 20.1%  
Dividend payout %16.123.9 67.4%   
Avg Mkt Cap Rs m24,580451,525 5.4%   
No. of employees `0000.83.7 20.3%   
Total wages/salary Rs m1,8013,649 49.4%   
Avg. sales/employee Rs Th10,748.910,184.4 105.5%   
Avg. wages/employee Rs Th2,395.2984.1 243.4%   
Avg. net profit/employee Rs Th2,641.12,998.5 88.1%   
INCOME DATA
Net Sales Rs m8,08337,764 21.4%  
Other income Rs m829848 97.8%   
Total revenues Rs m8,91338,612 23.1%   
Gross profit Rs m23414,138 1.7%  
Depreciation Rs m371,182 3.1%   
Interest Rs m223 7.8%   
Profit before tax Rs m1,02513,781 7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7522,662 28.2%   
Profit after tax Rs m1,98611,119 17.9%  
Gross profit margin %2.937.4 7.7%  
Effective tax rate %73.419.3 379.7%   
Net profit margin %24.629.4 83.5%  
BALANCE SHEET DATA
Current assets Rs m12,67830,947 41.0%   
Current liabilities Rs m2,4335,195 46.8%   
Net working cap to sales %126.768.2 185.9%  
Current ratio x5.26.0 87.5%  
Inventory Days Days33117 28.0%  
Debtors Days Days2285 26.4%  
Net fixed assets Rs m6917,027 0.4%   
Share capital Rs m160531 30.1%   
"Free" reserves Rs m11,46042,341 27.1%   
Net worth Rs m11,62142,877 27.1%   
Long term debt Rs m05 0.0%   
Total assets Rs m14,40049,684 29.0%  
Interest coverage x570.5595.0 95.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 73.9%   
Return on assets %13.822.4 61.6%  
Return on equity %17.125.9 65.9%  
Return on capital %23.632.2 73.2%  
Exports to sales %0.785.3 0.9%   
Imports to sales %18.622.9 81.1%   
Exports (fob) Rs m6032,198 0.2%   
Imports (cif) Rs m1,5038,654 17.4%   
Fx inflow Rs m18632,270 0.6%   
Fx outflow Rs m1,8218,775 20.8%   
Net fx Rs m-1,63523,496 -7.0%   
CASH FLOW
From Operations Rs m2,53110,379 24.4%  
From Investments Rs m-8,270-4,135 200.0%  
From Financial Activity Rs m-386-6,241 6.2%  
Net Cashflow Rs m-6,1253 -185,590.9%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.8 16.9%  
FIIs % 1.6 19.0 8.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.2 125.0%  
Shareholders   41,647 31,796 131.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 22, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS